Proteomics of the Amniotic Fluid in Assessment of the Placenta. Relevance for Preterm Birth

Placenta

Volumn 29, Issue SUPPL., 2008, Pages 95-101

  Buhimschi, I A ^a   Buhimschi, C S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amniotic fluid; Inflammation; Placenta; Prematurity; Proteomics; RAGE

Indexed keywords

BIOLOGICAL MARKER; DNA; RNA;

AMNION FLUID; ARTICLE; CLINICAL EXAMINATION; DISEASE CLASSIFICATION; DNA RNA HYBRIDIZATION; FETUS OUTCOME; FOLLOW UP; FUNISITIS; HISTOPATHOLOGY; HUMAN; INTRAUTERINE GROWTH RETARDATION; MEDICAL RESEARCH; NEWBORN SEPSIS; PHENOTYPE; PLACENTA DISORDER; PLACENTA FUNCTION; PREECLAMPSIA; PREMATURITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS;

AMNIOTIC FLUID; FEMALE; HUMANS; PLACENTA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREMATURE BIRTH; PROGNOSIS; PROTEOMICS;

EID: 40849116181     PISSN: 01434004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.placenta.2007.12.001     Document Type: Article

References (44)

1. Lieber C.D. Introduction to proteomics. Tools for the new biology (2002), Humana Press, Totowa, NJ
2. Buhimschi C.S., Weiner C.P., and Buhimschi I.A. Clinical proteomics. A novel diagnostic tool for the new biology of preterm labor. Part I: Proteomic tools. Obstet Gynecol Surv 61 (2006) 481-486
3. Buhimschi C.S., Weiner C.P., and Buhimschi I.A. Clinical proteomics Part II. The emerging role of proteomics over genomics in spontaneous preterm labor/birth. Obstet Gynecol Surv 61 (2006) 543-553
4. Wilkins M.R., Sanchez J.C., Gooley A.A., Appel R.D., Humphery-Smith I., Hochstrasser D.F., et al. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 13 (1996) 19-50
5. Green N.S., Damus K., Simpson J.L., Iams J., Reece E.A., Hobel C.J., et al. March Of Dimes Scientific Advisory Committee On Prematurity. Research agenda for preterm birth: recommendations from the March of Dimes. Am J Obstet Gynecol 193 (2005) 626-635
6. Pritchard K.I., Shepherd L.E., O'Malley F.P., Andrulis I.L., Tu D., Bramwell V.H., et al. National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354 (2006) 2103-2111
7. Buhimschi I.A., Buhimschi C.S., and Weiner C.P. Acute versus chronic inflammation: What makes the intra-uterine environment "unfriendly" to the fetus? From free radicals to proteomics. Am J Reprod Immunol 49 (2003) [abstract]:328
8. Vuadens F., Benay C., Crettaz D., Gallot D., Sapin V., Schneider P., et al. Identification of biologic markers of the premature rupture of fetal membranes: proteomic approach. Proteomics 3 (2003) 1521-1525
9. Gravett M.G., Novy M.J., Rosenfeld R.G., Reddy A.P., Jacob T., Turner M., et al. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA 292 (2004) 462-469
10. Buhimschi I.A., Christner R., and Buhimschi C.S. Proteomic biomarker analysis of amniotic fluid for identification of intra-amniotic inflammation. BJOG 112 (2005) 173-181
11. Michel P.E., Crettaz D., Morier P., Heller M., Gallot D., Tissot J.D., et al. Proteome analysis of human plasma and amniotic fluid by Off-Geltrade mark isoelectric focusing followed by nano-LC-MS/MS. Electrophoresis 27 (2006) 1169-1181
12. Ruetschi U., Rosen A., Karlsson G., Zetterberg H., Rymo L., Hagberg H., et al. Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. J Proteome Res 4 (2005) 2236-2242
13. Buhimschi I.A., Buhimschi C.S., Weiner C.P., Kimura T., Hamar B.D., Sfakianaki A.K., et al. Proteomic but not enzyme-linked immunosorbent assay technology detects amniotic fluid monomeric calgranulins from their complexed calprotectin form. Clin Diagn Lab Immunol 12 (2005) 837-844
14. Buhimschi I.A., Buhimschi C.S., Christner R., and Weiner C.P. Proteomics technology for the accurate diagnosis of inflammation in twin pregnancies. BJOG 112 (2005) 250-255
15. Buhimschi C.S., Pettker C.M., Magloire L.K., Martin R., Norwitz E., Funai E., et al. Proteomic technology and delayed interval delivery in multiple pregnancies. Int J Gynaecol Obstet 90 (2005) 48-50
16. Weiner C.P., Lee K.Y., Buhimschi C.S., Christner R., and Buhimschi I.A. Proteomic biomarkers that predict the clinical success of rescue cerclage. Am J Obstet Gynecol 192 (2005) 710-718
17. Warner S. Diagnostics + therapy = theranostics. Scientist 18 (2004) 38
18. Benirschke K. Examination of the placenta. Obstet Gynecol 18 (1961) 309-333
19. Naeye R.L. Disorders of the placenta and decidua. Disorder of the placenta, fetus and neonate: diagnosis and clinical significance (1992), Mosby, St. Louis 118-247
20. Salafia C.M., Weigl C., and Silberman L. The prevalence and distribution of acute placental inflammation in uncomplicated term pregnancies. Obstet Gynecol 73 (1989) 383-389
21. Redline R.W. Placental pathology and cerebral palsy. Clin Perinatol 33 (2006) 503-516
22. Redline R.W., Faye-Petersen O., Heller D., Qureshi F., Savell V., and Vogler C. Amniotic infection syndrome: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol 6 (2003) 435-448
23. Bejar R., Wozniak P., Allard M., Benirschke K., Vaucher Y., Coen R., et al. Antenatal origin of neurologic damage in newborn infants. I. Preterm infants. Am J Obstet Gynecol 159 (1988) 357-363
24. De Felice C., Toti P., Laurini R.N., Stumpo M., Picciolini E., Todros T., et al. Early neonatal brain injury in histologic chorioamnionitis. J Pediatr 138 (2001) 101-104
25. Grafe M.R. The correlation of prenatal brain damage with placental pathology. Neuropathol Exp Neurol 53 (1994) 407-415
26. Redline R.W. Inflammatory responses in the placenta and umbilical cord. Semin Fetal Neonatal Med 11 (2006) 296-301
27. Kim C.J., Yoon B.H., Romero R., Moon J.B., Kim M., Park S.S., et al. Umbilical arteritis and phlebitis mark different stages of the fetal inflammatory response. Am J Obstet Gynecol 185 (2001) 496-500
28. Rogers B.B., Alexander J.M., Head J., McIntire D., and Leveno K.J. Umbilical vein interleukin-6 levels correlate with the severity of placental inflammation and gestational age. Hum Pathol 33 (2002) 335-340
29. Sampson J.E., Theve R.P., Blatman R.N., Shipp T.D., Bianchi D.W., Ward B.E., et al. Fetal origin of amniotic fluid polymorphonuclear leukocytes. Am J Obstet Gynecol 176 (1997) 77-81
30. Liberatori S., Bini L., De Felice C., Magi B., Marzocchi B., Raggiaschi R., et al. A two-dimensional protein map of human amniotic fluid at 17 weeks' gestation. Electrophoresis 18 (1997) 2816-2822
31. Kuwata H., Yip T.T., Yip C.L., Tomita M., and Hutchens T.W. Bactericidal domain of lactoferrin: detection, quantitation, and characterization of lactoferricin in serum by SELDI affinity mass spectrometry. Biochem Biophys Res Commun 245 (1998) 764-773
32. Fung E.T., Yip T.T., Lomas L., Wang Z., Yip C., Meng X.Y., et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 115 (2005) 783-789
33. Cook Moats L. Speech to print (2000), Paul H. Brooks Publishing, Baltimore p. 21-58
34. Buhimschi C.S., Bhandari V., Hamar B., Bahtiyar M.O., Zhao G., Sfakianaki A.K., et al. Proteomic profiling of the amniotic fluid to detect inflammation, infection, and neonatal sepsis. PLoS Med 4 (2007) e18
35. Buhimschi C.S., Buhimschi I.A., Abdel-Razeq S., Rosenberg V.A., Thung S.F., Zhao G., et al. Proteomic biomarkers of intra-amniotic inflammation: relationship with funisitis and early-onset sepsis in the premature neonate. Pediatr Res 61 (2007) 318-324
36. Buhimschi I.A., Zhao G., Pettker C.M., Bahtiyar M.O., Magloire L.K., Thung S., et al. The receptor for advanced glycation end products (RAGE) system in women with intraamniotic infection and inflammation. Am J Obstet Gynecol 196 2 (2007) 181 e1-13
37. Heizmann C.W., Fritz G., and Schafer B.W. S100 proteins: structure, functions and pathology. Front Biosci 7 (2002) 1356-1368
38. Vogl T., Propper C., Hartmann M., Strey A., Strupat K., van den Bos C., et al. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem 274 (1999) 25291-25296
39. Robinson M.J., and Hogg N. A comparison of human S100A12 with MRP-14 (S100A9). Biochem Biophys Res Commun 275 (2000) 865-870
40. Gottsch J.D., Li Q., Ashraf F., O'Brien T.P., Stark W.J., and Liu S.H. Cytokine-induced calgranulin C expression in keratocytes. Clin Immunol 91 (1999) 34-40
41. Foell D., Kucharzik T., Kraft M., Vogl T., Sorg C., Domschke W., et al. Neutrophil derived human S100A12 (ENRAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52 (2003) 847-853
42. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97 (1999) 889-901
43. Stern D., Yan S.D., Yan S.F., and Schmidt A.M. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 54 (2002) 1615-1625
44. Chavakis T., Bierhaus A., and Nawroth P.P. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 6 (2004) 1219-1225